AstraZeneca adds live chat option to Nexium, Crestor sites

Share this article:
Visitors to and can now hit a “click to chat” button to chat with a live AstraZeneca customer service rep.

The feature, which can be accessed through the sites' "Contact us” pages, will be operated by the same nurses, pharmacists and customer service reps that handle customer calls, and as with calls, will be available weekdays from 8 am-6 pm. Those clicking during off-hours will get a popup box advising them that no reps are available and that they can try back during regular business hours.

“AstraZeneca understands that our consumers want flexibility, especially when it comes to health information,” said senior director, AstraZeneca Information Center Donna Holder. “This new resource enables consumers to have easier access to the information they seek through the convenience of a real-time online channel.”

The company is one of the first in the sector to use click-to-chat, said Don Keane, VP marketing and product strategy for Angel, which offers chat and Interactive Voice Response programs. AstraZeneca launched a “Call Me Now” feature on the sites in October, giving visitors the option to skip telephone prompts, recordings and waiting on hold and instead receive an immediate phone call from a live rep.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...